161 related articles for article (PubMed ID: 32721503)
1. Rational design of EGFR dimerization-disrupting peptides: A new strategy to combat drug resistance in targeted lung cancer therapy.
Liu Q; Zhou J; Gao J; Ma W; Wang S; Xing L
Biochimie; 2020 Sep; 176():128-137. PubMed ID: 32721503
[TBL] [Abstract][Full Text] [Related]
2. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
[TBL] [Abstract][Full Text] [Related]
3. Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer.
Chen L; Fu W; Zheng L; Liu Z; Liang G
J Med Chem; 2018 May; 61(10):4290-4300. PubMed ID: 29136465
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
5. A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models.
Singh SS; Mattheolabakis G; Gu X; Withers S; Dahal A; Jois S
Eur J Med Chem; 2021 Apr; 216():113312. PubMed ID: 33667849
[TBL] [Abstract][Full Text] [Related]
6. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
7. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Liao BC; Lin CC; Yang JC
Curr Opin Oncol; 2015 Mar; 27(2):94-101. PubMed ID: 25611025
[TBL] [Abstract][Full Text] [Related]
8. Conformationally constrained peptides target the allosteric kinase dimer interface and inhibit EGFR activation.
Fulton MD; Hanold LE; Ruan Z; Patel S; Beedle AM; Kannan N; Kennedy EJ
Bioorg Med Chem; 2018 Mar; 26(6):1167-1173. PubMed ID: 28911855
[TBL] [Abstract][Full Text] [Related]
9. Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer.
Tong CWS; Wu WKK; Loong HHF; Cho WCS; To KKW
Cancer Lett; 2017 Oct; 405():100-110. PubMed ID: 28774798
[TBL] [Abstract][Full Text] [Related]
10. In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.
Patel H; Pawara R; Surana S
Comput Biol Chem; 2018 Jun; 74():167-189. PubMed ID: 29627693
[TBL] [Abstract][Full Text] [Related]
11. [Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].
Ni L; Nie L
Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):110-115. PubMed ID: 29526178
[TBL] [Abstract][Full Text] [Related]
12. Targeting EGFR
Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
[TBL] [Abstract][Full Text] [Related]
13. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
14. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
15. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
16. [TKI Resistance for T790M Mutation].
Wang H; Guo R; Zhang L
Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):245-50. PubMed ID: 25936890
[TBL] [Abstract][Full Text] [Related]
17. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
18. Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
Kobayashi Y; Azuma K; Nagai H; Kim YH; Togashi Y; Sesumi Y; Chiba M; Shimoji M; Sato K; Tomizawa K; Takemoto T; Nishio K; Mitsudomi T
Mol Cancer Ther; 2017 Feb; 16(2):357-364. PubMed ID: 27913578
[TBL] [Abstract][Full Text] [Related]
19. [Treatment strategy for activating EGFR-mutated non-small cell lung cancer after failure of first-generation EGFR-TKIs].
Asami K
Gan To Kagaku Ryoho; 2014 May; 41(5):533-8. PubMed ID: 24916999
[TBL] [Abstract][Full Text] [Related]
20. Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance.
Patel H; Pawara R; Ansari A; Surana S
Eur J Med Chem; 2017 Dec; 142():32-47. PubMed ID: 28526474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]